27
Participants
Start Date
July 8, 2019
Primary Completion Date
September 26, 2024
Study Completion Date
September 26, 2024
ATL001
ATL001 infusion
Pembrolizumab
Checkpoint inhibitor
Memorial Sloan Kettering Cancer Center, New York
Instituto de Investigación Sanitaria Fundación Jimenez Díaz, Madrid
Centro Integral Oncologico Clara Campal Hospital Universitario HM Sanchinarro, Madrid
Moffitt Cancer Center, Tampa
Universitätsklinikum Essen, Essen
Hospital Clinico Universitario de Valencia, Valencia
Centre Hospitalier Lyon Sud, Pierre-Bénite
Yale University School of Medicine, New Haven
Universitätsklinikum Carl Gustav Carus Dresden, Dresden
Hospital Clinic de Barcelona, Barcelona
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham
Cambridge University Hospitals NHS Foundation Trust, Addenbrookes Hospital, Cambridge
The Newcastle upon Tyne Hospitals NHS Foundation Trust, Freeman Hospital, Newcastle upon Tyne
University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton
The Leeds Teaching Hospitals NHS Trust, St James's University Hospital, Leeds
University College London Hospitals (UCLH) NHS Foundation Trust, University College Hospital, London
Guys and St Thomas' NHS Foundation Trust, Guy's Hospital, London
The Christie NHS Foundation Trust, Christie Hospital, Manchester
Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester
Lead Sponsor
Achilles Therapeutics UK Limited
INDUSTRY